Reaktionsgleichung
[CH3:1]/[CH:2]=[C:3]1\[C@H:4]([CH2:25][C:26]([O:28]CCC2C=CC(O)=C(O)C=2)=[O:27])[C:5]([C:21]([O:23]C)=[O:22])=[CH:6][O:7][C@H:8]\1[O:9][C@@H:10]1[O:15][C@H:14]([CH2:16][OH:17])[C@@H:13]([OH:18])[C@H:12]([OH:19])[C@H:11]1[OH:20].[OH-].[K+]>CO.Cl>[CH3:1]/[CH:2]=[C:3]1\[C@H:4]([CH2:25][C:26]([OH:28])=[O:27])[C:5]([C:21]([OH:23])=[O:22])=[CH:6][O:7][C@H:8]\1[O:9][C@@H:10]1[O:15][C@H:14]([CH2:16][OH:17])[C@@H:13]([OH:18])[C@H:12]([OH:19])[C@H:11]1[OH:20]Komponenten
Reagenzien, Katalysatoren, Lösungsmittel 2
Reaktionsbedingungen
- Temperatur
- 10 °C
Versuchsvorschrift
Oleuropein (1 g) is dispersed in 50 ml of methanol. The solution is cooled to about 10° C. and treated with stirring with about 2 g of potassium hydroxide pellets. The mixture is allowed to warm to room temperature and after about 6 hours, the reaction mixture is diluted with about 60 ml of 6 N HCl (pH about 7.5) and evaporated to dryness. The chromatographic purification of the product mixture provides oleoside [Formula I; R=glycosyl, R1 =methyl]. The purified oleoside is formulated into a solid oral dosage form containing about 250 mg of oleoside. Alternatively, oleoside is dissolved in sterile isotonic saline at a concentration of about 5 mg per ml to provide a parenteral dosage form for use in accordance with the method of this invention.
Aufarbeitung
- additiontreated
- temperatureto warm to room temperature and after about 6 hours
- customevaporated to dryness
- customThe chromatographic purification of the product mixture
Quellen und Nachweise
- ORD-Eintrag
- ord-f5805e756d0f462ea97b989119230c15
- Quelldatensatz
- uspto-grants-2000_09
- Patentnummer
- US06117844
Verknüpfte Notizen
Wird geladen…